It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The therapeutic efficacy of adoptive T cell therapy is largely restricted by reduced viability and dysfunction of CD8+ T cells. Continuous antigen stimulation disrupts the expansion, effector function, and metabolic fitness of CD8+ T cells, leading to their differentiation into an exhausted state within the tumor microenvironment (TME). While the function of the cell cycle negative regulator p16 in senescent cells is well understood, its role in T cell exhaustion remains unclear. In this study, we demonstrated that TCR stimulation of CD8+ T cells rapidly upregulates p16 expression, with its levels positively correlating with TCR affinity. Chronic TCR stimulation further increased p16 expression, leading to CD8+ T cell apoptosis and exhaustion differentiation, without inducing DNA damage or cell senescence. Mechanistic investigations revealed that p16 downregulates mTOR, glycolysis, and oxidative phosphorylation (OXPHOS) associated gene expression, resulting in impaired mitochondrial fitness, reduced T cell viability, and diminished effector function. Furthermore, the deletion of p16 significantly enhances the persistence of CD8+ T cells within tumors and suppresses the terminal exhaustion of tumor-infiltrating T cells. Overall, our findings elucidate how increased p16 expression reshapes T cell intracellular metabolism, drives T cell apoptosis and exhaustion differentiation, and ultimately impairs T cell anti-tumor function.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); China Pharmaceutical University, Institute of Pharmaceutical Sciences, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793)
2 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
3 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Soochow University, Institutes of Biology and Medical Sciences (IBMS), Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694)
4 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); The Affiliated Suzhou Hospital of Nanjing Medical University, Department of Oncology, Suzhou, China (GRID:grid.452511.6)
5 China Pharmaceutical University, Institute of Pharmaceutical Sciences, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793)
6 The Affiliated Suzhou Hospital of Nanjing Medical University, Department of Oncology, Suzhou, China (GRID:grid.452511.6)